Featured Research

from universities, journals, and other organizations

Biomarkers For Alzheimer's Disease Can Be Trusted In Clinical Trials

Date:
November 19, 2007
Source:
IOS Press
Summary:
The best-established biomarkers for Alzheimer's disease have a low natural variation over two years. The results speak for the inclusion of these biomarkers in clinical trials of novel drugs against Alzheimer's disease.

The best-established biomarkers for Alzheimer's disease have a low natural variation over two years. The results speak for the inclusion of these biomarkers in clinical trials of novel drugs against Alzheimer's disease.

Related Articles


"We show that the best-established diagnostic biomarkers for Alzheimer's disease stay at basically the same level during two years in patients with early Alzheimer's disease. This means that the biomarkers could be useful for detecting even minor biochemical changes induced by treatment in the clinical trials of novel drugs against Alzheimer's," says Henrik Zetterberg, Associate Professor at the Sahlgrenska Academy.

Dr Zetterberg and colleagues analyzed cerebrospinal fluid from more than 80 patients with mild cognitive impairment. Some of these patients developed full-blown Alzheimer's disease. The measured levels of the tau and amyloid-b proteins were compared in samples drawn from the same patients two years apart.

"If a novel drug candidate actually stops or slows down the neurodegenerative disease process in Alzheimer's disease, we should expect a normalized tau concentration in cerebrospinal fluid in patients on active treatment. Such a change should be readily detectable also in a small and inexpensive pilot study, given the low intra-individual variation in biomarker levels over time that was detected in our study," Dr Zetterberg says.

Alzheimer's disease is an age-related brain-damaging disorder that results in progressive cognitive impairment and death. Three decades of progress have resulted in a profound understanding of the molecular mechanisms underlying the disease. In the past 10 years, this knowledge has translated into a range of targets for therapy, the most promising of which is amyloid-b.

The results are presented by researchers at the Sahlgrenska Academy at Göteborg University, Sweden, in the November 2007 issue of the Journal of Alzheimer's Disease,12:3 (November 2007).

Article title: Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years

Authors: Henrik Zetterberg, Mona Pedersen, Karin Lind, Maria Svensson, Sindre Rolstad, Carl Eckerström, Steinar Syversen, Ulla-Britt Mattsson, Chrisina Ysander, Niklas Mattsson, Arto Nordlund, Hugo Vanderstichele, Eugeen Vanmechelen, Michael Jonsson, Åke Edman, kaj Blennow and Anders Wallin


Story Source:

The above story is based on materials provided by IOS Press. Note: Materials may be edited for content and length.


Cite This Page:

IOS Press. "Biomarkers For Alzheimer's Disease Can Be Trusted In Clinical Trials." ScienceDaily. ScienceDaily, 19 November 2007. <www.sciencedaily.com/releases/2007/11/071115093129.htm>.
IOS Press. (2007, November 19). Biomarkers For Alzheimer's Disease Can Be Trusted In Clinical Trials. ScienceDaily. Retrieved March 4, 2015 from www.sciencedaily.com/releases/2007/11/071115093129.htm
IOS Press. "Biomarkers For Alzheimer's Disease Can Be Trusted In Clinical Trials." ScienceDaily. www.sciencedaily.com/releases/2007/11/071115093129.htm (accessed March 4, 2015).

Share This


More From ScienceDaily



More Mind & Brain News

Wednesday, March 4, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Former NFL Players Donate Brains to Science

Former NFL Players Donate Brains to Science

Reuters - US Online Video (Mar. 3, 2015) — Super Bowl champions Sidney Rice and Steve Weatherford donate their brains, post-mortem, to scientific research into repetitive brain trauma. Jillian Kitchener reports. Video provided by Reuters
Powered by NewsLook.com
Alzheimer's Protein Plaque Found In 20-Year-Olds

Alzheimer's Protein Plaque Found In 20-Year-Olds

Newsy (Mar. 3, 2015) — Researchers found an abnormal protein associated with Alzheimer&apos;s disease in the brains of 20-year-olds. Video provided by Newsy
Powered by NewsLook.com
This Nasal Treatment Could Help Ease Migraine Pain

This Nasal Treatment Could Help Ease Migraine Pain

Newsy (Mar. 2, 2015) — Researchers gave lidocaine to 112 patients, and about 88 percent of the subjects said they needed less migraine-relief medicine the next day. Video provided by Newsy
Powered by NewsLook.com
How Facebook Use Can Lead To Depression

How Facebook Use Can Lead To Depression

Newsy (Mar. 1, 2015) — Margaret Duffy of the University of Missouri talks about her study on the social network and the envy and depression that Facebook use can cause. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins